Digital Health company Livongo Health said today that it is partnering with Glytec to develop a diabetes management solution that includes insulin titration. The companies plan to expand Glytec’s eGlycemic Management System to improve health outcomes in patients with diabetes.
Glytec touted that its suite of FDA-cleared dosing algorithms for IV, subcutaneous and pediatric insulin dosing already yield clinical outcomes such as insulin titration to goal in 11 days and sustained drops of A1C of 2.6%. Together, the companies hope to integrate medication data, provide medication monitoring and optimize adherence.
“After more than a decade of accruing great results on the inpatient side with our therapy management software, and early successes in the outpatient realm, Glytec is excited to be furthering our reach through this partnership with such a pioneer and leader as Livongo,” chief medical officer Dr. Andrew Rhinehart said in prepared remarks. “The integrated, provider decision support solution that Glytec and Livongo together offer represents another exciting step forward in personalized and data-driven diabetes care. Livongo’s advanced approach to diabetes management, coupled with Glytec’s unique ability to support both basal and bolus insulin titration, provides the opportunity to truly disrupt the way the industry and providers address this critical aspect of diabetes care.”
“Partnering with FDA-cleared insulin algorithm companies allows us to connect more dots for our members and their providers,” Livongo chief medical officer Dr. Jennifer Schneider added. “As a doctor and a person living with diabetes, I am excited about how this partnership will make it easier to stay healthy.”
